| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Allena Pharmaceuticals Inc (NASDAQ: ALNA)
ALNA Technical Analysis
5
| As on 9th Nov 2022 ALNA STOCK Price closed @ 0.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.76 & Strong Sell for SHORT-TERM with Stoploss of 1.12 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ALNASTOCK Price
| Open | 0.01 | Change | Price | % |
| High | 0.01 | 1 Day | 0.00 | 0.00 |
| Low | 0.01 | 1 Week | 0.00 | 0.00 |
| Close | 0.01 | 1 Month | -0.01 | -50.00 |
| Volume | 173948 | 1 Year | -1.18 | -99.16 |
| 52 Week High 1.39 | 52 Week Low 0.01 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| NVDA | 138.25 | 2.15% |
| LMDX | 0.02 | 0.00% |
| MARA | 27.42 | 1.86% |
| OPTT | 0.50 | 35.14% |
| PONO | 1.72 | 2.38% |
| TELL | 1.00 | 0.00% |
| SMCI | 32.64 | -6.93% |
| BTB | 0.03 | 0.00% |
| TWKS | 4.47 | -0.45% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ALNA Daily Charts |
ALNA Intraday Charts |
Whats New @ Bazaartrend |
ALNA Free Analysis |
|
|
ALNA Important Levels Intraday
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
| RESISTANCE | 0.01 |
ALNA Forecast December 2024
| 4th UP Forecast | 0.7 |
| 3rd UP Forecast | 0.48 |
| 2nd UP Forecast | 0.34 |
| 1st UP Forecast | 0.21 |
| 1st DOWN Forecast | -0.19 |
| 2nd DOWN Forecast | -0.32 |
| 3rd DOWN Forecast | -0.46 |
| 4th DOWN Forecast | -0.68 |
ALNA Weekly Forecast
| 4th UP Forecast | 0.40 |
| 3rd UP Forecast | 0.27 |
| 2nd UP Forecast | 0.20 |
| 1st UP Forecast | 0.12 |
| 1st DOWN Forecast | -0.10 |
| 2nd DOWN Forecast | -0.18 |
| 3rd DOWN Forecast | -0.25 |
| 4th DOWN Forecast | -0.38 |
ALNA Forecast2024
| 4th UP Forecast | 2.78 |
| 3rd UP Forecast | 1.89 |
| 2nd UP Forecast | 1.34 |
| 1st UP Forecast | 0.79 |
| 1st DOWN Forecast | -0.77 |
| 2nd DOWN Forecast | -1.32 |
| 3rd DOWN Forecast | -1.87 |
| 4th DOWN Forecast | -2.76 |
Allena Pharmaceuticals Inc ( NASDAQ USA Symbol : ALNA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ALNA Business Profile
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts. Address: One Newton Executive Park, Newton, MA, United States, 02462
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service